Similarly, recent studies have shown that SIAH1 can ubiquitinate YB-1 at K304 and target it for proteasomal degradation, thereby reducing the resistance of epithelial ovarian cancer cells to cisplatin [175]. This evidence concerns the gene YBX1 and ovarian carcinoma.